GeNeuro News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.10.23	GeNeuro and Verily Collaborate to Advance Long-COVID Research (Businesswire)
16.11.22	GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab (Businesswire)
16.11.22	GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab (Businesswire)
16.11.22	GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID (Businesswire)
13.12.21	GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID (Businesswire)
13.12.21	Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID (Businesswire)
31.01.20	GeNeuro Announces Successful €17.5 Million Private Placement (Businesswire)
10.07.19	Schweizer Aktien werden nicht mehr in der EU gehandelt - Das sind die Auswirkungen (finanzen.ch) Die Unstimmigkeiten zwischen der EU und der Schweiz über ein Rahmenabkommen zum gegenseitigen Marktabkommen haben spürbare Folgen: Seit letzter Woche dürfen an EU-Handelsplätzen keine Schweizer Werte mehr gehandelt werden.» mehr
22.02.18	GeNeuro Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Businesswire)
12.02.18	GeNeuro Reports Cash and Revenue at December 31, 2017 (Businesswire)
09.01.18	GeNeuro Completes Patient Enrollment in Phase 2a Study of GNbAC1 in Type 1 Diabetes (Businesswire)
03.01.18	GeNeuro: Annual Report on the Liquidity Contract with Gilbert Dupont (Businesswire)
21.12.17	GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study (Businesswire)
02.11.17	GeNeuro Reports Cash and Revenue for Q3 2017 (Businesswire)
30.10.17	GeNeuro to Host Conference Call and Webcast Today Following the Presentation of Promising Post-Hoc Analyses at the MSParis2017 Congress (Businesswire)
28.09.17	GeNeuro Reports 2017 Half-Year Results and Provides Corporate Update (Businesswire)
19.09.17	GeNeuro and Servier to Present Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis at MSParis2017 (Businesswire)
11.09.17	GeNeuro and Collaborators Publish Data Supporting Role of Retroviral Pathogenic Envelope Protein in Type 1 Diabetes (T1D) (Businesswire)
28.08.17	GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis (Businesswire)
31.07.17	GeNeuro Updates on Cash, Revenue and Activities at Q2 2017 (Businesswire)
12.07.17	GeNeuro: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont (Businesswire)
10.05.17	GeNeuro reports cash and revenue for Q1 2017 (Businesswire)
07.12.16	GeNeuro and Servier Announce ANGEL-MS Extension Clinical Study in Multiple Sclerosis (Businesswire)
24.10.16	GeNeuro Reports Cash and Revenue for Q3 2016 (Businesswire)
29.09.16	GeNeuro Reports 2016 Half-Year Results and Provides Corporate Update (Businesswire)
14.09.16	GeNeuro Phase 2b Multiple Sclerosis Study Recruitment Reaches Halfway Mark Ahead of Schedule (Businesswire)
06.09.16	GeNeuro Announces Participation at Upcoming Investor Events (Businesswire)
03.08.16	GeNeuro: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
18.07.16	GeNeuro Reports Cash and Revenue for Q2 2016 (Businesswire)
04.07.16	GeNeuro: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont (Businesswire)
04.07.16	GeNeuro: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
20.06.16	GeNeuro joins the CAC® Mid & Small, CAC® Small and CAC® All-Tradable Euronext indexes (Businesswire)
03.06.16	GeNeuro: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
31.05.16	GeNeuro Announces First Patients Treated in Phase 2b Study for Multiple Sclerosis (Businesswire)
31.05.16	GeNeuro Announces First Patients Treated in Phase 2b Study for Multiple Sclerosis (Businesswire)
04.05.16	GeNeuro Announces the End of Stabilization Operations in Connection with IPO and the Implementation of a Liquidity Contract (Businesswire)
28.04.16	GeNeuro Reports Cash and Revenue for Q1 2016 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu GeNeuro SA

Aktien Top/Flop

Meistgelesene Nachrichten